Cargando…

Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis

PURPOSE: To study efficacy of anti-vascular endothelial growth factor (anti-VEGF) in resolution of macular edema in epidemic retinitis (ER). METHODS: In this retrospective, comparative study, patients diagnosed as ER with central macular thickness (CMT) ≥ 600 μm on SD-OCT at presentation were studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawali, Ankush A, Mohan, Ashwin, Mehta, Ruchir, Mahendradas, Padmamalini, Srinivasan, Sanjay, Shetty, Bhujang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690540/
https://www.ncbi.nlm.nih.gov/pubmed/32823413
http://dx.doi.org/10.4103/ijo.IJO_439_20
_version_ 1783614091213930496
author Kawali, Ankush A
Mohan, Ashwin
Mehta, Ruchir
Mahendradas, Padmamalini
Srinivasan, Sanjay
Shetty, Bhujang
author_facet Kawali, Ankush A
Mohan, Ashwin
Mehta, Ruchir
Mahendradas, Padmamalini
Srinivasan, Sanjay
Shetty, Bhujang
author_sort Kawali, Ankush A
collection PubMed
description PURPOSE: To study efficacy of anti-vascular endothelial growth factor (anti-VEGF) in resolution of macular edema in epidemic retinitis (ER). METHODS: In this retrospective, comparative study, patients diagnosed as ER with central macular thickness (CMT) ≥ 600 μm on SD-OCT at presentation were studied. Eyes which did not receive intravitreal anti-VEGF formed group A and eyes receiving additional anti-VEGF formed group B. Eyes receiving anti-VEGF monotherapy were studied separately. Cases with subsequent OCT scans with interval of more than 20 days and cases without OCT scan at the resolution were excluded. Treatment details, visual outcome, and days to resolution of macular edema were studied. RESULTS: Mean CMT in group A (n = 8) was 820.1 μm (range 607-1004 μm) and in Group B (n = 4) was 756.0 μm (range 603-1000 μm). Macular edema resolved in 34.8 days (range: 16-65) and 39.0 days (range: 21–45) in group A and B, respectively. Two eyes with anti-VEGF monotherapy recovered in 45 and 18 days, respectively. Mean corrected distance visual acuity (CDVA) at presentation in group A was 19.1 (range: 0–61) ETDRS letters and in group B was 14.3 (range: 0–35) ETDRS letters. Mean CDVA improved to 65.7 (range: 0–85) and 50.8 (range: 20–76) ETDRS letters in group A and B, respectively. Anti-VEGF monotherapy eyes improved from 35 and 46 ETDRS letters to 70 and 85 ETDRS letters, respectively. CONCLUSION: Additional anti-VEGF therapy has no added advantage in speed of resolution of macular edema due to ER. A randomized controlled trial with steroids sparing “anti-VEGF monotherapy” may verify our observations.
format Online
Article
Text
id pubmed-7690540
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-76905402020-12-30 Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis Kawali, Ankush A Mohan, Ashwin Mehta, Ruchir Mahendradas, Padmamalini Srinivasan, Sanjay Shetty, Bhujang Indian J Ophthalmol Original Article PURPOSE: To study efficacy of anti-vascular endothelial growth factor (anti-VEGF) in resolution of macular edema in epidemic retinitis (ER). METHODS: In this retrospective, comparative study, patients diagnosed as ER with central macular thickness (CMT) ≥ 600 μm on SD-OCT at presentation were studied. Eyes which did not receive intravitreal anti-VEGF formed group A and eyes receiving additional anti-VEGF formed group B. Eyes receiving anti-VEGF monotherapy were studied separately. Cases with subsequent OCT scans with interval of more than 20 days and cases without OCT scan at the resolution were excluded. Treatment details, visual outcome, and days to resolution of macular edema were studied. RESULTS: Mean CMT in group A (n = 8) was 820.1 μm (range 607-1004 μm) and in Group B (n = 4) was 756.0 μm (range 603-1000 μm). Macular edema resolved in 34.8 days (range: 16-65) and 39.0 days (range: 21–45) in group A and B, respectively. Two eyes with anti-VEGF monotherapy recovered in 45 and 18 days, respectively. Mean corrected distance visual acuity (CDVA) at presentation in group A was 19.1 (range: 0–61) ETDRS letters and in group B was 14.3 (range: 0–35) ETDRS letters. Mean CDVA improved to 65.7 (range: 0–85) and 50.8 (range: 20–76) ETDRS letters in group A and B, respectively. Anti-VEGF monotherapy eyes improved from 35 and 46 ETDRS letters to 70 and 85 ETDRS letters, respectively. CONCLUSION: Additional anti-VEGF therapy has no added advantage in speed of resolution of macular edema due to ER. A randomized controlled trial with steroids sparing “anti-VEGF monotherapy” may verify our observations. Wolters Kluwer - Medknow 2020-09 2020-08-20 /pmc/articles/PMC7690540/ /pubmed/32823413 http://dx.doi.org/10.4103/ijo.IJO_439_20 Text en Copyright: © 2020 Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kawali, Ankush A
Mohan, Ashwin
Mehta, Ruchir
Mahendradas, Padmamalini
Srinivasan, Sanjay
Shetty, Bhujang
Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis
title Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis
title_full Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis
title_fullStr Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis
title_full_unstemmed Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis
title_short Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis
title_sort anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690540/
https://www.ncbi.nlm.nih.gov/pubmed/32823413
http://dx.doi.org/10.4103/ijo.IJO_439_20
work_keys_str_mv AT kawaliankusha antivascularendothelialgrowthfactorinthetreatmentofmacularedemainepidemicretinitis
AT mohanashwin antivascularendothelialgrowthfactorinthetreatmentofmacularedemainepidemicretinitis
AT mehtaruchir antivascularendothelialgrowthfactorinthetreatmentofmacularedemainepidemicretinitis
AT mahendradaspadmamalini antivascularendothelialgrowthfactorinthetreatmentofmacularedemainepidemicretinitis
AT srinivasansanjay antivascularendothelialgrowthfactorinthetreatmentofmacularedemainepidemicretinitis
AT shettybhujang antivascularendothelialgrowthfactorinthetreatmentofmacularedemainepidemicretinitis